MGX-001 Shows Curative Potential, IND Submission Expected in 2026
"I am excited by the direction we are headed as we enter 2026, led by MGX-001, our wholly owned hemophilia A program. MGX-001 recently demonstrated curative factor VIII activity in non-human primates with clear dose-dependent activity and no identifiable off-target editing, representing a therapy with best-in-class treatment potential," said Jian Irish, CEO. "The study informs our anticipated clinical dose regimen and based on recent regulatory engagement, we feel well positioned to file our IND/CTA submissions before year end 2026 and initiate a first-in-human study in 2027. The recent steps we took to strategically reprioritize our pipeline provide us a strengthened balance sheet with runway anticipated into the fourth quarter of 2027. Looking ahead, our new corporate name represents our focus and commitment to delivering curative genetic medicines to patients and accelerating development of these medicines by strategically deploying our most advanced, proprietary technologies built on our foundational science of metagenomics."
Trade with 70% Backtested Accuracy
Analyst Views on MGX
About MGX
About the author
Investigation into Metagenomi Directors' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Metagenomi Therapeutics, Inc. breached their fiduciary duties to shareholders, which could impact corporate governance and shareholder rights.
- Legal Fee Arrangement: The firm operates on a contingency fee basis, meaning shareholders can pursue legal remedies without upfront costs, thereby lowering the barrier to participation in the investigation.
- Potential Remedies: Long-term shareholders may seek corporate governance reforms, fund recovery, or court-approved financial awards, which can enhance transparency and accountability, ultimately increasing shareholder value.
- Importance of Shareholder Participation: Involvement from shareholders can improve company policies and oversight mechanisms; Halper Sadeh LLC represents investors globally in seeking compensation for securities fraud and corporate misconduct, having successfully implemented reforms that recovered millions for defrauded investors.
OPENAI CFO SARAH FRIAR ANNOUNCES PARTICIPATION OF A16Z, D.E. SHAW VENTURES, MGX, TPG, AND T. ROWE PRICE IN FUNDING ROUND
Funding Round Announcement: OpenAI, along with several venture capital firms including C.F.O. Sarah Friar, is participating in a new funding round.
Investors Involved: The funding round includes notable investors such as 16Z, D.E. Shaw Ventures, MGX, TPG, and T. Rowe Price.
Metagenomi Reports FY Earnings with Significant Revenue Decline
- Earnings Report: Metagenomi's FY GAAP EPS stands at -$2.36, aligning with market expectations, yet the overall performance fails to boost investor confidence amid challenging market conditions.
- Revenue Decline: The company reported revenue of $25.2 million, reflecting a significant 51.8% year-over-year decline, missing the market estimate of $28.43 million, indicating severe operational challenges.
- Market Reaction: The revenue miss is likely to negatively impact Metagenomi's stock price, as investor confidence in the company's future growth potential diminishes in light of disappointing financial results.
- Industry Context: With increasing competition in the health tech sector, Metagenomi must implement effective strategies to restore growth and enhance its market share to navigate these turbulent times.
Metagenomi Therapeutics Renames Company, Plans IND Submission for MGX-001 in 2026
- Strategic Evolution: Metagenomi Therapeutics has changed its name to reflect its strategic focus on late-stage preclinical assets, aiming to leverage its advanced gene-editing capabilities to drive the success of therapeutic programs, particularly in hemophilia A.
- Clinical Advancement: MGX-001 has demonstrated curative FVIII activity in non-human primates with no identifiable off-target editing, with plans to submit IND/CTA in Q4 2026 and initiate first-in-human studies in 2027.
- Cash Runway: The company anticipates a cash runway extending through Q4 2027, ensuring financial stability while advancing MGX-001 and other therapeutic projects, thereby enhancing investor confidence.
- Pipeline Prioritization: Through strategic pipeline prioritization, Metagenomi is focusing on MGX-001 and other potential therapies, showcasing its strong competitiveness and market potential in the gene therapy sector.
Metagenomi Therapeutics Renames to Reflect Focus on Gene Therapy, MGX-001 IND Submission Planned for 2026
- Strategic Evolution: Metagenomi Therapeutics has changed its name to reflect its strategic evolution focused on late-stage preclinical assets, particularly the MGX-001 program for hemophilia A, which is expected to submit IND/CTA in 2026, marking a significant advancement in gene therapy.
- Clinical Readiness: MGX-001 demonstrated curative FVIII activity in non-human primates with no identifiable off-target editing, supporting its potential as a best-in-class treatment, with plans to initiate first-in-human studies in 2027 to further advance clinical development.
- Cash Runway: The company anticipates a cash runway extending through Q4 2027, ensuring sufficient funding to support the advancement of MGX-001 and other therapeutic projects, thereby enhancing its competitive position in the market.
- Pipeline Prioritization: Through strategic pipeline prioritization, Metagenomi is focusing on MGX-001 and other secreted protein deficiencies, showcasing the company's strong technological capabilities and promising market outlook in the field of gene editing.
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.
Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.
Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.
Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.
Investigation into Metagenomi Directors' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Metagenomi Therapeutics, Inc. breached their fiduciary duties to shareholders, which could impact corporate governance and shareholder rights.
- Legal Fee Arrangement: The firm operates on a contingency fee basis, meaning shareholders can pursue legal remedies without upfront costs, thereby lowering the barrier to participation in the investigation.
- Potential Remedies: Long-term shareholders may seek corporate governance reforms, fund recovery, or court-approved financial awards, which can enhance transparency and accountability, ultimately increasing shareholder value.
- Importance of Shareholder Participation: Involvement from shareholders can improve company policies and oversight mechanisms; Halper Sadeh LLC represents investors globally in seeking compensation for securities fraud and corporate misconduct, having successfully implemented reforms that recovered millions for defrauded investors.
OPENAI CFO SARAH FRIAR ANNOUNCES PARTICIPATION OF A16Z, D.E. SHAW VENTURES, MGX, TPG, AND T. ROWE PRICE IN FUNDING ROUND
Funding Round Announcement: OpenAI, along with several venture capital firms including C.F.O. Sarah Friar, is participating in a new funding round.
Investors Involved: The funding round includes notable investors such as 16Z, D.E. Shaw Ventures, MGX, TPG, and T. Rowe Price.
Metagenomi Reports FY Earnings with Significant Revenue Decline
- Earnings Report: Metagenomi's FY GAAP EPS stands at -$2.36, aligning with market expectations, yet the overall performance fails to boost investor confidence amid challenging market conditions.
- Revenue Decline: The company reported revenue of $25.2 million, reflecting a significant 51.8% year-over-year decline, missing the market estimate of $28.43 million, indicating severe operational challenges.
- Market Reaction: The revenue miss is likely to negatively impact Metagenomi's stock price, as investor confidence in the company's future growth potential diminishes in light of disappointing financial results.
- Industry Context: With increasing competition in the health tech sector, Metagenomi must implement effective strategies to restore growth and enhance its market share to navigate these turbulent times.
Metagenomi Therapeutics Renames Company, Plans IND Submission for MGX-001 in 2026
- Strategic Evolution: Metagenomi Therapeutics has changed its name to reflect its strategic focus on late-stage preclinical assets, aiming to leverage its advanced gene-editing capabilities to drive the success of therapeutic programs, particularly in hemophilia A.
- Clinical Advancement: MGX-001 has demonstrated curative FVIII activity in non-human primates with no identifiable off-target editing, with plans to submit IND/CTA in Q4 2026 and initiate first-in-human studies in 2027.
- Cash Runway: The company anticipates a cash runway extending through Q4 2027, ensuring financial stability while advancing MGX-001 and other therapeutic projects, thereby enhancing investor confidence.
- Pipeline Prioritization: Through strategic pipeline prioritization, Metagenomi is focusing on MGX-001 and other potential therapies, showcasing its strong competitiveness and market potential in the gene therapy sector.
Metagenomi Therapeutics Renames to Reflect Focus on Gene Therapy, MGX-001 IND Submission Planned for 2026
- Strategic Evolution: Metagenomi Therapeutics has changed its name to reflect its strategic evolution focused on late-stage preclinical assets, particularly the MGX-001 program for hemophilia A, which is expected to submit IND/CTA in 2026, marking a significant advancement in gene therapy.
- Clinical Readiness: MGX-001 demonstrated curative FVIII activity in non-human primates with no identifiable off-target editing, supporting its potential as a best-in-class treatment, with plans to initiate first-in-human studies in 2027 to further advance clinical development.
- Cash Runway: The company anticipates a cash runway extending through Q4 2027, ensuring sufficient funding to support the advancement of MGX-001 and other therapeutic projects, thereby enhancing its competitive position in the market.
- Pipeline Prioritization: Through strategic pipeline prioritization, Metagenomi is focusing on MGX-001 and other secreted protein deficiencies, showcasing the company's strong technological capabilities and promising market outlook in the field of gene editing.
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.
Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.
Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.
Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.
